235 related articles for article (PubMed ID: 32782240)
1. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.
Abdallah N; Rajkumar SV; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Kumar SK
Blood Cancer J; 2020 Aug; 10(8):82. PubMed ID: 32782240
[TBL] [Abstract][Full Text] [Related]
2. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.
Abdallah N; Baughn LB; Rajkumar SV; Kapoor P; Gertz MA; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Ketterling R; Bergsagel L; Greipp P; Kumar SK
Clin Cancer Res; 2020 Dec; 26(24):6581-6588. PubMed ID: 33008815
[TBL] [Abstract][Full Text] [Related]
3. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.
Rajkumar SV; Gupta V; Fonseca R; Dispenzieri A; Gonsalves WI; Larson D; Ketterling RP; Lust JA; Kyle RA; Kumar SK
Leukemia; 2013 Aug; 27(8):1738-44. PubMed ID: 23515097
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
[TBL] [Abstract][Full Text] [Related]
5. The real-world outcomes of multiple myeloma patients treated with daratumumab.
Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Gjerdrum LMR; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Dokhi M; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
PLoS One; 2021; 16(10):e0258487. PubMed ID: 34644367
[TBL] [Abstract][Full Text] [Related]
6. Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.
D'Agostino M; Zaccaria GM; Ziccheddu B; Rustad EH; Genuardi E; Capra A; Oliva S; Auclair D; Yesil J; Colucci P; Keats JJ; Gambella M; Bringhen S; Larocca A; Boccadoro M; Bolli N; Maura F; Gay F
Clin Cancer Res; 2020 Sep; 26(18):4832-4841. PubMed ID: 32616499
[TBL] [Abstract][Full Text] [Related]
7. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
Abdallah N; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Rajkumar SV; Kumar SK
Blood Adv; 2020 Aug; 4(15):3509-3519. PubMed ID: 32750129
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
[TBL] [Abstract][Full Text] [Related]
10.
Hui H; Fuller KA; Eresta Jaya L; Konishi Y; Ng TF; Frodsham R; Speight G; Yamada K; Clarke SE; Erber WN
J Clin Pathol; 2023 Nov; 76(11):763-769. PubMed ID: 36113967
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
12. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
13. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for multiple myeloma.
Wallington-Beddoe CT; Pitson SM
Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
[No Abstract] [Full Text] [Related]
15. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
16. Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma.
Rabani H; Ziv M; Lavi N; Aviv A; Suriu C; Shalata A; Haddid Y; Tadmor T
Leuk Res; 2020 Dec; 99():106476. PubMed ID: 33171301
[TBL] [Abstract][Full Text] [Related]
17. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
[TBL] [Abstract][Full Text] [Related]
19. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
[TBL] [Abstract][Full Text] [Related]
20. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
